Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 100
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Eur Acad Dermatol Venereol ; 36(8): 1292-1299, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35412683

RESUMEN

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. OBJECTIVES: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. METHODS: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. RESULTS: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. CONCLUSIONS: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Dermatitis Atópica , Eccema , Anticuerpos Monoclonales Humanizados , Dermatitis Atópica/tratamiento farmacológico , Método Doble Ciego , Humanos , Pandemias , Estudios Prospectivos , Prurito , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
12.
Neuropeptides ; 42(5-6): 663-70, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18715640

RESUMEN

The distribution and modification of the tachykinins Substance P (SP) and neurokinin A (NKA), their precursor beta-preprotachykinins (beta-PPT) and the receptors involved in their activity, NK-1 and NK-2, were studied in trinitrobenzensulphonic acid (TNB) colitis. Rats were intrarectally treated with a 120 mg/ml of TNB solution and sacrificed at various times after colitis induction. During the acute phases of colitis, a marked decrease in tissue SP and NKA levels were observed along with an increased transcription of beta-PPT mRNA in the neurons of the myenteric plexus and an increased myeloperoxidase activity, which is an index of the tissue's inflammatory status. De novo expression of both NK(1) and NK(2) receptor mRNA was observed during the acute phase of TNB-colitis in mesenchymal cells around dilated submucosal vessels but their expression in smooth muscle cells of the muscularis mucosae and propria was moderately down-regulated. The peptide levels, myeloperoxidase activity and gene expression of tachykinin receptors were then restored during the late phases (2-4 weeks after the apten administration) while beta-PPT mRNA remained highly expressed in the myenteric plexus ganglia showing that SP and NKA are involved in repair processes. These results point to the enhanced release of tachykinins during the initial phase of colitis and a restoration of this neuropeptide pool in the healing of the tissue.


Asunto(s)
Colitis/inducido químicamente , Colitis/metabolismo , Receptores de Neuroquinina-1 , Receptores de Neuroquinina-2 , Taquicininas/metabolismo , Ácido Trinitrobencenosulfónico/farmacología , Animales , Peso Corporal , Colitis/patología , Colitis/fisiopatología , Colon/citología , Colon/metabolismo , Colon/patología , Masculino , Peroxidasa/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/genética , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/genética , Receptores de Neuroquinina-2/metabolismo , Taquicininas/genética
13.
Auton Autacoid Pharmacol ; 27(1): 39-46, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17199874

RESUMEN

1. The effect of montelukast or MEN91507, selective leucotriene CysLT1 receptor antagonists, on antigen-induced airway inflammation and bronchoconstriction were compared in anaesthetized guinea-pigs. 2. In sensitized animals, ovalbumin (0.3 mg kg(-1), i.v.)-induced microvascular leakage in trachea, intrapulmonary airways, total lung (parenchyma and intrapulmonary airways) and urinary bladder was reduced by MEN91507 (0.01-1 micromol kg(-1), i.v.), whereas montelukast (0.01-1 micromol kg(-1), i.v.) antagonized the effect of the antigen only in the lung and urinary bladder. 3. Ovalbumin (1 mg kg(-1), i.v.)-induced bronchoconstriction was dose dependently antagonized by MEN91507 (10-30 micromol kg(-1), i.v.), whereas the effect of montelukast (0.1-30 micromol kg(-1), i.v.) was marginal (15-30% inhibition). Neither MEN91507 nor montelukast (30 micromol kg(-1), i.v.) affected the bronchoconstrictor response induced by acetylcholine (0.3 micromol kg(-1), i.v.) in sensitized animals. 4. It is concluded that montelukast and MEN91507 display a differential activity against the effect of endogenous leucotrienes, despite the fact that both compounds show a similar antagonist profile against exogenous leucotrienes acting through CysLT1 receptors.


Asunto(s)
Antígenos/inmunología , Broncoconstricción/efectos de los fármacos , Inflamación/inducido químicamente , Antagonistas de Leucotrieno/farmacología , Proteínas de la Membrana/antagonistas & inhibidores , Sistema Respiratorio/efectos de los fármacos , Sistema Respiratorio/patología , Acetatos/administración & dosificación , Acetatos/farmacología , Animales , Benzopiranos/farmacología , Ciclopropanos , Relación Dosis-Respuesta a Droga , Azul de Evans , Cobayas , Inflamación/patología , Inyecciones Intravenosas , Masculino , Ovalbúmina/administración & dosificación , Ovalbúmina/farmacología , Quinolinas/administración & dosificación , Quinolinas/farmacología , Receptores de Leucotrienos , Sistema Respiratorio/irrigación sanguínea , Sulfuros , Tetrazoles/farmacología
14.
Br J Pharmacol ; 173(8): 1329-38, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26758701

RESUMEN

BACKGROUND AND PURPOSE: The tachykinin NK2 receptor antagonist ibodutant is under Phase III clinical investigation to treat female patients with irritable bowel syndrome. The aim of this study was to investigate the NK2 receptor-related gender specificity in a model of colitis. EXPERIMENTAL APPROACH: Colitis was induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS, 0.5 mL, 30 mg·mL(-1) in 30% ethanol) in female and male guinea pigs. Electromyographic recording of the responses to colorectal distension (CRD) was made 3 days later. Ibodutant (0.33 , 0.65, 1.9 and 6.5 mg·kg(-1) ) was given s.c., 30 min before CRD. Release of neurokinin A and substance P from isolated mucosal and smooth muscle tissues following treatment with KCl (80 mM) or capsaicin (10 µM) was measured by EIA. Plasma pharmacokinetics of ibodutant following a single s.c. administration (0.73 or 2.1 mg·kg(-1) ) were measured over 24 h. KEY RESULTS: Ibodutant did not affect abdominal contractions in control animals. After TNBS-induced colitis, ibodutant prevented the increased visceral hypersensitivity to CRD in females, at lower doses than in males. Ibodutant pharmacokinetics did not differ between females and males. Tachykinins release was greater in smooth muscle than in mucosal samples. Capsaicin-stimulated release of tachykinins from inflamed mucosal samples from females was significantly lower than in males. CONCLUSIONS AND IMPLICATIONS: Ibodutant prevented abdominal nociception in a model of visceral hypersensitivity in guinea pigs with a greater efficacy in females than in males. Our results highlight a gender-related difference in colonic visceral hypersensitivity and mucosal nerve activation.


Asunto(s)
Colitis/metabolismo , Colon/metabolismo , Hiperalgesia/metabolismo , Receptores de Neuroquinina-2/metabolismo , Caracteres Sexuales , Dolor Visceral/metabolismo , Animales , Colitis/inducido químicamente , Colitis/prevención & control , Dipéptidos/administración & dosificación , Dipéptidos/sangre , Dipéptidos/farmacología , Modelos Animales de Enfermedad , Femenino , Cobayas , Hiperalgesia/prevención & control , Masculino , Tiofenos/administración & dosificación , Tiofenos/sangre , Tiofenos/farmacología , Ácido Trinitrobencenosulfónico , Dolor Visceral/prevención & control
15.
Neuroscience ; 34(1): 243-50, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2325850

RESUMEN

The aim of this study was to assess whether omega conotoxin fraction GVIA, a potent blocker of N- and L-type voltage-sensitive calcium channels, might interfere with reflex responses (micturition, blood pressure rise in spinal rats) produced by activation of capsaicin-sensitive sensory nerves of the rat urinary bladder. The effect of conotoxin was also investigated on reflex micturition persisting after capsaicin pretreatment. Following topical application onto the bladder, conotoxin did not affect the volume threshold to elicit micturition although it reduced the amplitude of volume-evoked bladder contractions. Likewise, topical conotoxin did not prevent the reflex rise in blood pressure elicited by sudden bladder distension or topical application of capsaicin onto the bladder. In contrast, topical lidocaine strongly prevented both reflex responses. After intrathecal administration, conotoxin produced a dose-dependent inhibition of volume-evoked bladder contractions and the cardiovascular reflex produced by mechanical or chemical stimulation of bladder nerves. Intrathecal conotoxin inhibited micturition also in rats pretreated with capsaicin (50 mg/kg s.c., 4 days before). Depolarization by high potassium (80 mM) produced release of both substance P- and calcitonin gene-related peptide-like immunoreactivity from superfused slices of the dorsal half of rat spinal cord. Capsaicin (1 microM) produced a similar effect, and a previous exposure to capsaicin prevented the effect of potassium. Conotoxin (0.1 microM) significantly reduced (about 50%) the potassium-induced release of neuropeptides from the dorsal half of the rat spinal cord. These findings indicate that conotoxin-sensitive calcium channels in the rat spinal cord play a role in the neurotransmission along reflex pathways activated by stimulation of capsaicin-sensitive nerves in the urinary bladder.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Capsaicina/farmacología , Conotoxinas , Venenos de Moluscos/farmacología , Neuronas Aferentes/fisiología , Médula Espinal/metabolismo , Vejiga Urinaria/inervación , Micción/efectos de los fármacos , Animales , Presión Sanguínea/efectos de los fármacos , Bloqueadores de los Canales de Calcio/farmacología , Relación Dosis-Respuesta a Droga , Inyecciones Espinales , Masculino , Contracción Muscular/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Ratas , Ratas Endogámicas , Reflejo/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/fisiología
16.
Neuroscience ; 41(1): 295-301, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1711653

RESUMEN

Protons can release in a Ca(2+)-dependent manner, calcitonin gene-related peptide (CGRP)-like immunoreactivity from peripheral endings of capsaicin-sensitive afferents. Here we have studied the mechanism by which proton promotes CGRP-like immunoreactivity release and whether the neuropeptide released might exert a biological action. In muscle slices of guinea-pig urinary bladder high pH (pH 8 or 9) media neither enhanced CGRP-like immunoreactivity outflow nor affected the capsaicin-evoked CGRP-like immunoreactivity release. The CGRP-like immunoreactivity release evoked by superfusion with pH 5 medium was not affected by tetrodotoxin (0.3 microM) indomethacin (10 microM) or the protein kinase C inhibitor H-7 (30 microM). However, it was reduced by 35% in the presence of the voltage-sensitive Ca(2+)-channel antagonists nifedipine (1 microM) and omega-conotoxin (0.1 microM) and by 80% in presence of the capsaicin "antagonist" Ruthenium Red (10 microM). The CGRP-like immunoreactivity release by capsaicin (10 microM) was reduced by 80% in the presence of Ruthenium Red, and not affected by voltage-sensitive Ca(2+)-channel blockers, while that evoked by 80 mM K+ was decreased by 82% in the presence of nifedipine and omega-conotoxin. The Ca(2+)-channel agonist Bay K 8644 enhanced the high K(+)-evoked CGRP-like immunoreactivity release but not that induced by capsaicin or pH 5 medium. Exposure to pH 6 solution of one half of the neck of guinea-pig urinary bladder induced a slowly developing inhibition of electrically evoked contractions, that was absent in the half pre-exposed in vitro to a desensitizing dose of capsaicin.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Ácidos/farmacología , Péptido Relacionado con Gen de Calcitonina/metabolismo , Capsaicina/farmacología , Neuronas Aferentes/metabolismo , Neurosecreción/efectos de los fármacos , Vejiga Urinaria/inervación , omega-Conotoxinas , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina , Ácido 3-piridinacarboxílico, 1,4-dihidro-2,6-dimetil-5-nitro-4-(2-(trifluorometil)fenil)-, Éster Metílico/farmacología , Animales , Canales de Calcio/efectos de los fármacos , Canales de Calcio/fisiología , Capsaicina/antagonistas & inhibidores , Cobayas , Concentración de Iones de Hidrógeno , Indometacina/farmacología , Isoquinolinas/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Nifedipino/farmacología , Péptidos Cíclicos/farmacología , Piperazinas/farmacología , Potasio/farmacología , Rojo de Rutenio/farmacología , Tetrodotoxina/farmacología
17.
Neuroscience ; 38(3): 687-92, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2270140

RESUMEN

The mechanism of neuropeptide secretion induced by bradykinin from capsaicin-sensitive afferents was studied in guinea-pig atria. Both the inotropic response induced by bradykinin (0.1 microM) in the electrically driven isolated guinea-pig left atria and the bradykinin (10 microM)-induced release of calcitonin gene-related peptide calcitonin gene-related peptide-like immunoreactivity from slices of guinea-pig atria were abolished in vitro by capsaicin pretreatment or in the presence of indomethacin. Bradykinin-induced calcitonin gene-related peptide-like immunoreactive release was unaffected by tetrodotoxin (0.3 microM), the protein kinase C inhibitor, 1-(5-isoquinolinesulphonyl)-2-methylpiperazine (30 microM), nefedipine (1 microM) or Ruthenium Red (10 microM). It was significantly reduced by 79% in a Ca2(+)-free medium and by 52% in the presence of 0.1 microM omega-conotoxin (fraction GVIA). It is proposed that bradykinin releases calcitonin gene-related peptide from capsaicin-sensitive afferents in guinea-pig atria, via prostanoid generation. This mode of activation of the "efferent" function of capsaicin-sensitive nerves appears to be distinct from those produced by capsaicin or electrical field stimulation as they have been characterized in previous works. In fact, the bradykinin activation of capsaicin-sensitive afferents is not affected by tetrodotoxin and Ruthenium Red, but is partially sensitive to the selective blocker of N-type Ca2(+)-channels, omega-conotoxin.


Asunto(s)
Bradiquinina/farmacología , Péptido Relacionado con Gen de Calcitonina/metabolismo , Calcio/fisiología , Capsaicina/farmacología , Sistema de Conducción Cardíaco/metabolismo , Animales , Resistencia a Medicamentos , Estimulación Eléctrica , Cobayas , Atrios Cardíacos , Técnicas In Vitro , Masculino , Contracción Miocárdica , Radioinmunoensayo
18.
Neuroscience ; 37(2): 531-9, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-1723514

RESUMEN

We have compared the ability of capsaicin and resiniferatoxin, a natural diterpene present in the latex of plants of the Euphorbia family to excite and desensitize capsaicin-sensitive primary afferents in a variety of models. Both capsaicin and resiniferatoxin inhibited the twitch contractions of the rat isolated vas deferens and prevented, in a concentration-related manner, the effect of a subsequent challenge with 1 microM capsaicin (desensitization). Resiniferatoxin was 1000-10,000 times more potent than capsaicin in both cases. The time course of action of resiniferatoxin was much slower than that of capsaicin, suggesting a slower penetration rate in the tissue. The action of resiniferatoxin was blocked by Ruthenium Red, a proposed antagonist at the cation channel coupled to the capsaicin receptor. Both capsaicin and resiniferatoxin produced a contraction of the rat isolated urinary bladder. Resiniferatoxin was about as potent as capsaicin in this assay although it was 500-1000 times more potent than capsaicin in desensitizing the primary afferents to a subsequent challenge with capsaicin itself. Resiniferatoxin did not affect motility in the isolated vasa deferentia or urinary bladder from capsaicin-pretreated rats. After topical application onto the rat urinary bladder both resiniferatoxin (10 nM) and capsaicin (10 microM) increased bladder capacity as assessed in a volume-evoked micturition reflex model in rats without affecting micturition contraction. Intrarterial injection of resiniferatoxin or capsaicin in the ear of anesthetized rabbits evoked a systemic depressor reflex due to activation of paravascular nociceptors, resiniferatoxin being about three times more potent than capsaicin.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Capsaicina/farmacología , Diterpenos/farmacología , Terminaciones Nerviosas/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Nervios Periféricos/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Anestesia , Animales , Péptido Relacionado con Gen de Calcitonina/metabolismo , Capsaicina/antagonistas & inhibidores , Diterpenos/antagonistas & inhibidores , Oído Externo/inervación , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Terminaciones Nerviosas/metabolismo , Neuronas Aferentes/metabolismo , Nervios Periféricos/metabolismo , Conejos , Ratas , Ratas Endogámicas , Reflejo/efectos de los fármacos , Rojo de Rutenio/farmacología , Médula Espinal/citología , Médula Espinal/metabolismo , Sustancia P/metabolismo , Vejiga Urinaria/inervación , Micción/efectos de los fármacos , Conducto Deferente/inervación
19.
Br J Pharmacol ; 119(5): 985-9, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8922749

RESUMEN

1. Single pulse electrical field stimulation (EFS, 0.5 ms pulse width, 60 V at a frequency of 0.05 Hz) induced twitch contractions of mucosa-free circular muscle strips from the guinea-pig proximal colon which were abolished by atropine (0.3 microM), tetrodotoxin (0.3 microM) or omega-conotoxin GVIA (0.1 microM). 2. Various opioid receptor agonist concentration-dependently inhibited twitches with the following rank order of potency (EC50 values in brackets): U 50488 (0.31 nM) > dermorphin (4.3 nM) = dynorphin A (1-13) (6.2 nM) > [D-Ala2, N-MePhe4, Gly5-ol]-enkephalin (DAMGO, 33.5 nM) = [D-Ala2, D-Leu5]-enkephalin (DADLE, 60 nM) > [D-Pen2, D-Pen2, D-Pen5]-enkepahlin (DPDPE, 1144 nM). 3. Peptidase inhibitors (captopril, thiorphan and bestatin, 1 microM each) did not modify the amplitude of twitches. In the presence of peptidase inhibitors the concentration-response curve to dynorphin A (1-13) was displaced to the left to yield an EC50 of 0.35 nM, comparable to that of the selective kappa receptor agonist, U50488. The curves to the other opioid receptor agonist were unaffected by peptidase inhibitors. 4. DPDPE, DADLE, dermorphin and DAMGO consistently induced a concentration-unrelated transient increase in basal tone and a small and transient facilitation of twitches before development of their inhibitory effect. These transient excitatory effects were not observed upon application of dynorphin A (1-13) or U 50488. The contraction produced by DPDPE (30 nM) was largely inhibited (> 80%) by 1 microM atropine. 5. Twitches suppression induced by dynorphin A (1-13) (30 nM) was partly reversed (46 +/- 8%, n = 6) by naloxone (0.3 microM). The potent and selective kappa opioid receptor antagonist nor-binaltorphimine (Nor-BNI, 3-100 nM)) did not affect the amplitude of twitches and potently antagonized (pKB 9.83 +/- 0.09, n = 10) the inhibitory effect of dynorphin. 6. Naloxone (1-300 nM) concentration-dependently depressed the cholinergic twitches: this depressant effect was largely counteracted in the presence of apamin (0.1 microM) and NG-nitro-L-arginine (30 microM) which potentiated cholinergic twitches on their own. 7. Dynorphin A (1-13) (10 nM, n = 6) did not affect the contractile response to exogenous acetylcholine (1 microM), indicating that depression of evoked twitches occurs prejunctionally. 8. We conclude that multiple opioid receptors modulate cholinergic twitches in the circular muscle of guinea-pig proximal colon. While mu and delta opioid receptor agonists produced mixed excitatory and inhibitory effects, kappa opioid receptors, activated by sub-nanomolar concentrations of dynorphin A (1-13), mediate a powerful and pure prejunctional inhibition of acetylcholine release.


Asunto(s)
Colon/fisiología , Músculo Liso/fisiología , Receptores Colinérgicos/fisiología , Receptores Opioides kappa/fisiología , Acetilcolina/farmacología , Animales , Colon/efectos de los fármacos , Dinorfinas/farmacología , Estimulación Eléctrica , Encefalina Ala(2)-MeFe(4)-Gli(5) , Encefalina D-Penicilamina (2,5) , Leucina Encefalina-2-Alanina/farmacología , Encefalinas/farmacología , Cobayas , Técnicas In Vitro , Masculino , Músculo Liso/efectos de los fármacos , Naloxona/farmacología , Oligopéptidos/farmacología , Péptidos Opioides , Receptores Colinérgicos/efectos de los fármacos , Receptores Opioides kappa/antagonistas & inhibidores
20.
Br J Pharmacol ; 124(7): 1566-72, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9723972

RESUMEN

1. We have investigated the effect of nociceptin on the micturition reflex evoked by distension or topical application of capsaicin on the urinary bladder of urethane-anaesthetized rats. 2. Nociceptin produced a dose-dependent (3-100 nmol kg(-1) i.v.) transient suppression of the distension-evoked micturition reflex: its effect was not modified by guanethidine (68 micromol kg(-1) s.c.) nor by bilateral cervical vagotomy, alone or in combination, and by naloxone (1.2 micromol kg(-1) i.v.). 3. Nociceptin (100 nmol/kg i.v.) slightly (about 30%) inhibited the contractions of the rat bladder produced by pre- or postganglionic electrical stimulation of the pelvic nerve. 4. Nociceptin almost totally abolished the reflex component of the response to topical capsaicin (1 microg in 50 microl). 5. In the rat isolated bladder, submaximal contractions produced by electrical field stimulation were slightly reduced (25+/-4% inhibition) by 1 microM nociceptin. Nociceptin did not affect the contraction of the rat bladder induced by acetylcholine (10 microM) or ATP (1 mM). 6. These findings indicate that nociceptin exerts a naloxone-resistant suppression of the volume-evoked micturition reflex which involves inhibition of transmitter release from postganglionic bladder nerves. An inhibitory effect on bladder afferent nerves is also suggested.


Asunto(s)
Péptidos Opioides/farmacología , Reflejo/efectos de los fármacos , Micción/efectos de los fármacos , Animales , Capsaicina/antagonistas & inhibidores , Estimulación Eléctrica , Técnicas In Vitro , Masculino , Ratas , Ratas Wistar , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/inervación , Vejiga Urinaria/fisiología , Micción/fisiología , Nociceptina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA